Table 2. Comparison of treatment outcome, tumor volume, and neutrophil-to-lymphocyte ratio between low and high pulmonary function parameters divided by the cutoff values determined via maximal log-rank tests.
| Variables | FEV1/FVC ratio | FEV1 (% of predicted) | FVC (% of predicted) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ≥0.74 | <0.74 | P | ≥76 | <76 | P | ≥91 | <91 | P | |||
| N=74 | 24 | 50 | 31 | 43 | 18 | 56 | |||||
| Death | 0.01 | 0.04 | 0.01 | ||||||||
| No | 15 (63%) | 14 (28%) | 17 (55%) | 12 (28%) | 12 (67%) | 17 (30%) | |||||
| Yes | 9 (38%) | 36 (72%) | 14 (45%) | 31 (72%) | 6 (33%) | 39 (70%) | |||||
| Progression | 0.01 | 0.10 | 0.94 | ||||||||
| No | 11 (46%) | 7 (14%) | 11 (35%) | 7 (16%) | 5 (28%) | 13 (23%) | |||||
| Yes | 13 (54%) | 43 (86%) | 20 (65%) | 36 (84%) | 13 (72%) | 43 (77%) | |||||
| Local progression | 0.36 | 0.39 | 0.03 | ||||||||
| No | 15 (63%) | 24 (48%) | 14 (45%) | 25 (58%) | 5 (28%) | 34 (61%) | |||||
| Yes | 9 (38%) | 26 (52%) | 17 (55%) | 18 (42%) | 13 (72%) | 22 (39%) | |||||
| Distant progression | 0.20 | 0.01 | 0.01 | ||||||||
| No | 20 (83%) | 33 (66%) | 28 (90%) | 25 (58%) | 18 (100%) | 35 (63%) | |||||
| Yes | 4 (17%) | 17 (34%) | 3 (10%) | 18 (42%) | 0 (0%) | 21 (38%) | |||||
| N=70 | 22 | 48 | 29 | 41 | 18 | 52 | |||||
| Tumor volume (cc), mean ± SD | 145±111 | 123±103 | 0.42 | 109±98 | 146±108 | 0.14 | 101±109 | 141±103 | 0.17 | ||
| N=69 | 20 | 49 | 28 | 51 | 17 | 52 | |||||
| Neutrophil to lymphocyte ratio, mean ± SD | 2.6±1.9 | 2.5±1.3 | 0.86 | 2±0.9 | 2.9±1.6 | <0.01 | 1.9±0.9 | 2.7±1.6 | 0.01 | ||
FEV1, pretreatment forced expiratory volume in 1 second; FVC, forced vital capacity; SD, standard deviation.